{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:23:25Z","timestamp":1788985405974,"version":"build-2803163510"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"abstract":"<jats:p>Rosacea fulminans developed in a middle-aged White man 10\u2005days after initiating deucravacitinib for chronic plaque psoriasis. The painful papulopustular eruption resolved without scarring after discontinuation of deucravacitinib and treatment with a short course of oral prednisolone. To our knowledge, this case is notable as it is the first reported instance of rosacea fulminans linked to the use of a Janus kinase inhibitor.<\/jats:p>","DOI":"10.1093\/ced\/llae495","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T11:41:24Z","timestamp":1731670884000},"page":"1031-1032","source":"Crossref","is-referenced-by-count":2,"title":["Rosacea fulminans following initiation of deucravacitinib"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-7153","authenticated-orcid":false,"given":"Meryl","family":"Thomas","sequence":"first","affiliation":[{"name":"Sinclair DIRECT, Dermatology Investigational Research, Education and Clinical Trials Centre , Melbourne, VIC ,","place":["Australia"]},{"name":"Monash School of Medicine, Monash University , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Paranjape","sequence":"additional","affiliation":[{"name":"Sinclair DIRECT, Dermatology Investigational Research, Education and Clinical Trials Centre , Melbourne, VIC ,","place":["Australia"]},{"name":"Royal Children\u2019s Hospital , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Sinclair DIRECT, Dermatology Investigational Research, Education and Clinical Trials Centre , Melbourne, VIC ,","place":["Australia"]},{"name":"Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"2025042411075228100_llae495-B1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40257-017-0310-0","article-title":"Diagnosis and treatment of rosacea fulminans: a comprehensive review","volume":"19","author":"Walsh","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2025042411075228100_llae495-B2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00128071-200405030-00007","article-title":"Eosinophilic pustular folliculitis","volume":"5","author":"Ellis","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"2025042411075228100_llae495-B3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/jamadermatol.2020.4219","article-title":"Psoriasis flares following systemic glucocorticoid exposure in patients with a history of psoriasis","volume":"157","author":"Gregoire","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025042411075228100_llae495-B4","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.19925","article-title":"Deucravacitinib in moderate-to-severe plaque psoriasis: pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)","volume":"38","author":"Strober","year":"2024","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2025042411075228100_llae495-B5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jdcr.2022.09.029","article-title":"A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis","volume":"30","author":"Lee","year":"2022","journal-title":"JAAD Case Rep"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae495\/60681122\/llae495.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/5\/1031\/60681122\/llae495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/5\/1031\/60681122\/llae495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:07:58Z","timestamp":1745507278000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/5\/1031\/7900916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":5,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,11,15]]},"published-print":{"date-parts":[[2025,4,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae495","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,11,15]]}}}